Introduction
============

Renal cell carcinoma (RCC) is one of the most common kidney carcinomas, which is the sixth leading cause of death in the USA. The male to female patient ratio is 1.6:1.0, with patient ages ranging from 40 to 70 years at diagnosis.[@b1-ott-11-5631] Clear cell renal cell carcinoma (ccRCC) is a major type of renal epithelial malignancies and is responsible for approximately 70%--80% of all RCC diagnoses.[@b2-ott-11-5631] It originates from the renal proximal tubule with a histological characteristic of clear cytoplasm with incidental eosinophilia areas. Surgical excision is considered the primary treatment method for ccRCC, by which most ccRCC patients will be cured. However, approximately 30% of new ccRCC cases show evidence of local or distant metastasis associated with poor prognosis, with a median survival time of only 13 months.[@b3-ott-11-5631]--[@b5-ott-11-5631] Therefore, it is necessary to identify sensitive and specific ccRCC targets and to develop novel therapeutic strategies for ccRCC.

Long noncoding RNAs (lncRNAs) are a newly discovered kind of noncoding RNAs (ncRNAs) that are defined as RNA transcripts longer than 200 nucleotides and are not or only partially translated into proteins.[@b6-ott-11-5631] Recent studies have suggested that lncRNAs play crucial roles in a range of biological processes, including cell proliferation, apoptosis and differentiation, and in cancer migration and metastasis.[@b7-ott-11-5631]--[@b12-ott-11-5631] Numerous dys-regulated lncRNAs have been identified in various tumors. HOXA-AS2 promotes breast cancer proliferation and invasion by manipulating miR-520c-3p expression.[@b13-ott-11-5631] XIST promotes pancreatic cancer proliferation by modulating the miR-133a/EGFR axis.[@b14-ott-11-5631] Moreover, several kinds of lncRNAs have been reported as new potential survival predictors for cancer patients, such as HOTAIR, HOTTIP, MALAT1 and CCAT1.[@b15-ott-11-5631]--[@b18-ott-11-5631] Recently, some studies have reported certain lncRNAs as prognostic biomarkers for ccRCC. For example, decreased expression levels of lnc-ZNF180-2, CADM1-AS1 and TCL6 are correlated with a worse prognosis in ccRCC patients in terms of shorter progression-free survival and cancer-specific survival.[@b19-ott-11-5631]--[@b21-ott-11-5631] However, more valuable, potential lncRNA biomarkers and their molecular mechanisms need to be identified to improve the clinical prognosis of ccRCC patients.

DHRS4 antisense RNA 1 (*DHRS4-AS1*) is a 3,052-bp spliced and polyadenylated noncoding RNA transcribed from intron 1 of the DHRS4 gene in the antisense direction that controls the local epigenetic status of each gene promoter within the DHRS4 gene cluster in a discriminatory manner.[@b22-ott-11-5631],[@b23-ott-11-5631] In our study, we found reduced expression levels of *DHRS4-AS1* in ccRCC tissues compared with adjacent non-tumor tissues and that the expression levels of *DHRS4-AS1* were inversely related to clinicopathological features and ccRCC patients' prognosis. Moreover, consistent with in vitro results, we demonstrated that *DHRS4-AS1* played a critical role in diminishing ccRCC cell proliferation, migration and invasion during ccRCC progression by a series of in vitro assays. Our results suggest that lncRNA *DHRS4-AS1* could represent a new indicator of poor prognosis and may be a potential novel therapeutic target for ccRCC patients.

Materials and methods
=====================

Clinical samples and cell culture
---------------------------------

In this study, fresh tumor and matched adjacent normal tissue samples were collected from patients who underwent radical nephrectomy or nephron-sparing surgery between 2012 and 2017 in the First Affiliated Hospital of Harbin Medical University. None of the patients received chemotherapy or radiotherapy prior to surgery. The clinicopathological information was obtained from patients' history record including patient age, overall survival duration, tumor cell differentiation, T category, clinical disease stage and lymph node status. All ccRCC cases were confirmed by a senior pathologist, samples were staged according to the tumor node metastasis (TNM) classification and criteria of the World Health Organization (WHO), and tumor grade was assessed in accordance with the WHO criteria. All tissue samples were immediately stored in liquid nitrogen until use. This study protocol conformed to clinical research guidelines and was approved by the research ethics committee of the First Affiliated Hospital of Harbin Medical University. Written informed consent was obtained from all patients who participated in this study. Cell lines 786-O, 769-P, HK-2 and 293T were purchased in 2016--2017 from the Chinese Academy of Science Committee Type Culture Collection Cell Bank (Shanghai, People's Republic of China). Two ccRCC cell lines, 786-O and 769-P, were cultured in RPMI-1640 (Thermo Fisher Scientific, Waltham, MA, USA) medium supplemented with 10% fetal bovine serum (FBS). Normal renal cell line HK-2 and 293T cells were cultured in DMEM (Thermo Fisher Scientific) supplemented with 10% FBS.

Bioinformatics analysis databases
---------------------------------

The ccRCC patients' clinical and RNA-Seq data were obtained from The Cancer Genome Atlas project (TCGA) (<https://tcga-data.nci.nih.gov/>).[@b24-ott-11-5631] The expression of lncRNAs was quantified by a customized data analysis pipeline that included the steps of quality control, alignment and expression quantification. The *DHRS4-AS1* methylation data were obtained from University of California Santa Cruz (UCSC) (<http://genome.ucsc.edu/>). A gene sets enrichment analysis was performed using Gene Set Enrichment Analysis (GSEA) software (<http://software.broadinstitute.org/gsea/index.jsp>) with the MSigDB C2 CP: KEGG gene sets collection (186 gene sets available). Gene sets with a false discovery rate (FDR) value \<0.01 after performing 1,000 permutations were considered significantly enriched.[@b25-ott-11-5631]

RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR)
-----------------------------------------------------------------------------

Total RNA was isolated by TRIzol reagent (Thermo Fisher Scientific, Carlsbad, CA, USA) according to the manufacturer's instructions. One µg of total RNA was reverse-transcribed into cDNA using High-Capacity cDNA Reverse Transcriptase Kits (Toyobo, Osaka, Japan). The level of *DHRS4-AS1* relative to the control gene, GAPDH, was determined by qRT-PCR using a Lightcycler-480II (Hoffman-La Roche Ltd., Basel, Switzerland). The PCR conditions were as follows: 95°C for 10 min, 40 cycles of 95°C for 15 s, and 60°C for 60 s. PCR amplification was performed in triplicate. Changes in threshold cycle (CT) values were calculated by the CT (2^−ΔΔCT^) method.

Lentiviral construction and production
--------------------------------------

Synthesized full-length *DHRS4-AS1* (NR_023921.2) was directly cloned into a pLVX vector through EcoRI and BamHI using an In-Fusion Cloning kit (Clontech, Beijing, China). Lentiviral packaging was performed in 293T cells. Briefly, 293T cells were transiently transfected with pLVX plasmid and the packaging plasmids pLP1, pLP2 and pLP/VSVG using a calcium phosphate-based transfection method. Supernatant containing lentiviral particles was harvested 3 days post-transfection and was centrifuged at 2,000 rpm for 10 min and filtered through a 0.45-µm filter to remove cellular debris. Then, the crude lentivirus was concentrated by a Lenti-X concentration kit (Clontech). The purified lentivirus was stored at −80°C.

Demethylation treatment using 5-Aza-2′-deoxycytidine (Aza)
----------------------------------------------------------

Treatment of RCC cell line using Aza was added to the medium.[@b26-ott-11-5631] Briefly, cells were treated with 4, 8 and 16 µM Aza (MedChemExpress, Monmouth, NJ, USA) for 72 h and harvested for RNA extraction, DMSO was added to cells as the control experiment.

Cell proliferation assay
------------------------

A cell proliferation assay was carried out using the Cell Counting Kit-8 (CCK-8) according to the manufacturer's instructions (CCK-8; Dojindo Molecular Technologies, Inc., Kyushu, Japan). Briefly, cells were seeded in a 96-well plate at 3 × 10^3^ cells per well. Cell proliferation was assessed after culturing for 24, 48 and 72 h. After adding 10 µL of CCK-8 reagents per well and incubating at 37°C for 2 h, the absorbance was measured at 450 nm using a microplate reader (BioTek, Winooski, VT, USA).

Colony formation assay
----------------------

For the colony formation assay, cells were seeded in six-well plates at 500 cells per well and cultured in RPMI-1640 with 10% FBS for 10 days. Colonies were fixed with 4% formaldehyde and stained with 0.1% crystal violet. Colonies with a diameter greater than 1 mm were counted.

Determination of cell apoptosis and cell cycle by flow cytometry
----------------------------------------------------------------

Apoptosis was analyzed with the Annexin V-PE Apoptosis Detection Kit (BD Biosciences, San Jose, CA, USA) according to the manufacturer's instructions. Briefly, cells were washed and resuspended in 1× binding buffer. Then, 100 µL of the cell solution (1 × 10^5^ cells) was mixed with 5 µL of Annexin V-PE and 5 µL of 7-AAD and the cells were kept on ice for 15 min in the dark. Next, 400 µL of 1× binding buffer was added to each tube for immediate analysis by flow cytometry (Becton Dickinson, Mountain View, CA, USA). The cell cycle was evaluated by flow cytometry using the Cycle TEST™ PLUS DNA Reagent Kit (BD Biosciences). Briefly, indicated numbers of cells were plated in 6-well plates. The cells were collected and centrifuged at 400× *g* for 5 min. Then, 250 µL of Solution A (trypsin buffer) was added to each tube and gently mixed by tapping the tube by hand, allowing Solution A to react for 10 min at room temperature. Next, 200 µL of Solution B (trypsin inhibitor and RNase buffer) was added to each tube, followed by incubation for 10 min. Then, 200 µL of cold (2°C--8°C) Solution C (propidium iodide stain solution) was added to each tube, and then the tubes were incubated for 10 min in the dark on ice. The cells were analyzed by flow cytometry (Becton Dickinson). Each assay was carried out triplicate.

Wound-healing assay
-------------------

Cells were seeded in 24-well plates at 1 × 10^5^ cells per well and incubated at 37°C in 5% CO~2~ for 24 h. To reduce cell proliferation, the cells were maintained in serum-free medium throughout the experiment. An approximate 0.4--0.5-mm line was scraped using the fine end of sterile pipette tips. Then, the plate was washed with 1× PBS three times. Images were captured using an inverted microscope and analyzed using ImageJ software (Rawak Software Inc., Stuttgart, Germany).

Transwell assay
---------------

Briefly, approximately 1 × 10^5^ cancer cells were suspended in 150 µL serum-free medium added to the upper chamber and a total of 600 µL medium with 10% serum was added to the bottom chamber as a chemoattractant. Cells were seeded in the 24-well Boyden chamber (8 µm; Corning Incorporated, Corning, NY, USA) and incubated for 24 h. After wiping off the non-migrating cells in the upper chamber attentively with cotton swabs, the cells on the polycarbonate membranes were fixed with 4% paraformaldehyde and stained with crystal violet. The cells were counted in five random fields on each membrane.

Western blot
------------

Cells were lysed to obtain proteins using radio immunoprecipitation assay. Proteins were separated by 12.5% or 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred to nitrocellulose filter membrane (GE Amersham, Germany). After blocking in 5% non-fat milk, the membrane was immunoblotted overnight at 4°C with primary antibodies: rabbit monoclonal antibody against human (1:1,000 dilution; Wanleibio, Beijing, China) and β-actin (1:5,000 dilution; Sigma-Aldrich Co., St Louis, MO, USA). A secondary antibody, horseradish peroxidase-conjugated anti-rabbit IgG antibody (1:2,000 dilution; ZSGB-BIO, Beijing, China), was incubated with the membrane for 1 h after three washes with TBST. Signals were detected with electricity chemistry lumina detection reagent (Beyotime, Shanghai, China). The images were obtained by Quantity One (Bio-Rad Laboratories Inc., Hercules, CA, USA).

Statistical analysis
--------------------

The statistical analysis was performed with GraphPad Prism 7.0 (GraphPad Software Inc., San Diego, CA, USA) and the results are presented as the mean ± SD (SD). Chi-square tests were performed to explore the associations between *DHRS4-AS1* levels and clinical and pathologic factors. Overall survival was calculated as the time from surgery until the occurrence of death. The Kaplan--Meier method and log-rank test were used to compare the differences between patient groups. Survival data were evaluated using univariate and multivariate Cox proportional hazards models. *P*-values \<0.05 were considered statistically significant.

Results
=======

The expression of *DHRS4-AS1* is diminished in ccRCC cell lines and tissues
---------------------------------------------------------------------------

Considering that survival prognosis in patients with ccRCC is extremely variable, we analyzed the high-throughput RNA-sequencing data of the ccRCC cohort from the TCGA database relative to survival prognosis. Seven lncRNAs were analyzed using a univariable Cox regression model and were significantly correlated with the patients' overall survival (*P* \< 0.001, [Table 1](#t1-ott-11-5631){ref-type="table"}). Higher expression levels of three lncRNAs corresponded to shorter survival (*LINC00338*, *PDXDC2P* and *SNHG3*). In contrast, higher expression levels of four lncRNAs (*DHRS4-AS1*, *RP11-815I9.4*, *RP11-732M18.3* and *OIP5-AS1*) were associated with longer survival. Because the FDR value is the most significant variable in the *DHRS4-AS1* COX analysis, we chose to focus on *DHRS4-AS1* in this study. To verify that *DHRS4-AS1* is downregulated in ccRCC tumor tissues, we analyzed the expression levels of *DHRS4-AS1* in 52 sets of ccRCC tumor tissues and their corresponding adjacent non-tumor tissues in patents from the First Affiliated Hospital of Harbin Medical University ([Figure 1A](#f1-ott-11-5631){ref-type="fig"}) and the TCGA database ([Figure 1B](#f1-ott-11-5631){ref-type="fig"}). The relative expression level of *DHRS4-AS1* in ccRCC tissues was significantly lower than that in the paired adjacent normal tissues, indicating that *DHRS4-AS1* may be involved in the pathogenesis of ccRCC. In the clinical classification, *DHRS4-AS1* levels in T1+T2 subjects were lower than those of T3+T4 subjects ([Figure 1C and D](#f1-ott-11-5631){ref-type="fig"}). Consistent with this, the *DHRS4-AS1* expression level was lower in patients with a high pathological stage ([Figure 1E and F](#f1-ott-11-5631){ref-type="fig"}). Reduced expression levels of *DHRS4-AS1* were observed in ccRCC cell lines 786-O and 769-P compared with the normal renal cell line HK-2 ([Figure 1G](#f1-ott-11-5631){ref-type="fig"}). Together, these data show that *DHRS4-AS1* expression is suppressed in ccRCC tissues and cells and is related to the clinical classification of ccRCC patients.

Downregulation of *DHRS4-AS1* is associated with adverse clinicopathological features and poor prognosis
--------------------------------------------------------------------------------------------------------

Next, we examined the potential clinical significance of *DHRS4-AS1* in ccRCC. Based on the relative expression levels of *DHRS4-AS1* (with the median value as the cutoff) in cancer/adjacent tissues, patients were divided into two groups: the *DHRS4-AS1* high expression group (n = 26) and the *DHRS4-AS1* low expression group (n = 26). The correlation between *DHRS4-AS1* expression and clinicopathological characteristics is shown in [Table 2](#t2-ott-11-5631){ref-type="table"}. Low *DHRS4-AS1* expression was positively associated with present lymph node metastasis (*P* = 0.048), high TNM stage (*P* = 0.025) and advanced pathological grade (*P* = 0.032). The expression level of *DHRS4-AS1* was not significantly associated with gender or age at surgery. Consistent with this, low *DHRS4-AS1* expression was also associated with a high TNM stage (*P* \< 0.001) and advanced pathological grade (*P* = 0.014) in a large cohort of 446 ccRCC patients retrieved from the TCGA database ([Table S1](#SD2-ott-11-5631){ref-type="supplementary-material"}). Low *DHRS4-AS1* expression was associated with an overall short survival time (*P* = 0.0255) by Kaplan--Meier analysis ([Figure 2A](#f2-ott-11-5631){ref-type="fig"}). Higher *DHRS4-AS1* expression suggested a good prognosis, which further confirmed the results from the large cohort of 446 ccRCC patients retrieved from the TCGA database (*P* = 0.0027) ([Figure 2B](#f2-ott-11-5631){ref-type="fig"}). Univariate and multivariate Cox proportional hazards analyses showed that *DHRS4-AS1*, TNM stage and pathological grade were independent prognostic factors for survival in 52 paired ccRCC patient samples ([Table 3](#t3-ott-11-5631){ref-type="table"}) and in 446 ccRCC patients retrieved from the TCGA database (Table S2). These results suggest that *DHRS4-AS1* may be a good diagnostic biomarker for ccRCC. We then used a receiver operating characteristic (ROC) curve to study the diagnostic value of *DHRS4-AS1* in distinguishing between ccRCC tissue and adjacent non-tumor tissue. The area under the curve (AUC) was calculated for the ROC curve and the AUC of the expression level of *DHRS4-AS1* was 0.801 ([Figure 2C](#f2-ott-11-5631){ref-type="fig"}), demonstrating that *DHRS4-AS1* has good potential as a biomarker.

KEGG pathway analysis for *DHRS4-AS1* signature target genes
------------------------------------------------------------

We explored the biological functions of *DHRS4-AS1* in tumorigenesis and progression in ccRCC. According to the prediction of the GSEA database results, the target gene enrichment results of the KEGG pathways in the present study are listed in [Figure 3](#f3-ott-11-5631){ref-type="fig"}. Pathways for ribosome, proteasome, oxidative phosphorylation, cell cycle, DNA replication, graft versus host disease, systemic lupus erythematosus, primary immunodeficiency, allograft rejection and natural killer cell-mediated cytotoxicity were enriched with the *DHRS4-AS1* target genes ([Figure 3A](#f3-ott-11-5631){ref-type="fig"}). The expression of *DHRS4-AS1* was negatively correlated with the expression of two gene sets previously defined in the TCGA KIRC (kidney renal clear cell carcinoma) data set, including one gene involved in the negative regulation of cell cycle genes ([Figure 3B](#f3-ott-11-5631){ref-type="fig"}) and one involved with DNA replication genes ([Figure 3C](#f3-ott-11-5631){ref-type="fig"}).

Exogenetic *DHRS4-AS1* expression suppressed ccRCC cell proliferation and promoted apoptosis in vitro
-----------------------------------------------------------------------------------------------------

To further examine the role of *DHRS4-AS1* in ccRCC cell proliferation, we overexpressed the lncRNA using purified lentivirus for Flag control or *DHRS4-AS1*. lncRNA *DHRS4-AS1* expression was comparatively lower in 786-O and 769-P cell lines than in the HK-2 cell line ([Figure 1G](#f1-ott-11-5631){ref-type="fig"}). Therefore, we selected 786-O and 769-P cells for the *DHRS4-AS1* overexpression assay and transfection efficiency was confirmed via qRT-PCR analysis ([Figure 4A](#f4-ott-11-5631){ref-type="fig"}). To determine the effect of *DHRS4-AS1* on the proliferation of ccRCC cells in vitro, we used CCK-8 assays and found that *DHRS4-AS1* overexpression obviously suppressed tumor cell proliferation compared with the control ([Figure 4B](#f4-ott-11-5631){ref-type="fig"}). *DHRS4-AS1-*depleted 786-O and 769-P cells formed significantly fewer colonies compared with the control in the colony formation assay ([Figure 4C](#f4-ott-11-5631){ref-type="fig"}), indicating an important role of *DHRS4-AS1* in inhibiting the growth of ccRCC cells. To identify the mechanism of *DHRS4-AS1* in suppressing cell proliferation, we studied whether *DHRS4-AS1* modulates cell cycle distribution by flow cytometry. The cell cycle analysis revealed that, compared with *DHRS4-AS1* overexpression, the Flag control caused significantly greater accumulation of ccRCC cells in the G0/G1 phase and a reduced number of cells in the S phase ([Figure 5A](#f5-ott-11-5631){ref-type="fig"}). These results suggest that the upregulation of *DHRS4-AS1* suppresses the proliferation of ccRCC cells possibly by inhibiting cell cycle progression.

We also studied whether *DHRS4-AS1* overexpression inhibits the proliferation of ccRCC cells by influencing apoptosis. Flow cytometry revealed that lentiviral transfection-induced *DHRS4-AS1* overexpression induced apoptosis in ccRCC cells ([Figure 5B](#f5-ott-11-5631){ref-type="fig"}), especially early apoptosis, indicating that *DHRS4-AS1* has a proapoptotic effect.

In vitro overexpression of *DHRS4-AS1* suppresses ccRCC cell line migration and invasion
----------------------------------------------------------------------------------------

Considering that lower *DHRS4-AS1* expression is significantly correlated with lymph node metastasis in ccRCC, we reasoned that *DHRS4-AS1* plays a role in inhibiting ccRCC cell motility. As shown in [Figure 6A](#f6-ott-11-5631){ref-type="fig"}, *DHRS4-AS1* overexpression significantly inhibited 786-O and 769-P cells' motility as measured by a wound-healing assay ([Figure 6B](#f6-ott-11-5631){ref-type="fig"}). The migration alternation was further confirmed by transwell assays ([Figure 6C and D](#f6-ott-11-5631){ref-type="fig"}). *DHRS4-AS1* overexpression suppressed 786-O and 769-P cell migration. Therefore, *DHRS4-AS1* has a critical role in the invasion and metastasis of ccRCC.

*DHRS4-AS1* controls the expression of epithelial-mesenchymal transition (EMT) associated genes in ccRCC cells
--------------------------------------------------------------------------------------------------------------

To further explore the mechanism by which *DHRS4-AS1* regulates cell migration and invasion, we examined protein levels of metastasis-associated and EMT-associated genes in ccRCC cells with overexpression of *DHRS4-AS1* expression. We found that, *DHRS4-AS1* overexpression significantly decreased the expression of mesenchymal marker genes including vimentin and N-cadherin and increased the expression of epithelial marker genes including E-cadherin, suggesting that overexpression of *DHRS4-AS1* could inhibit the EMT process ([Figure 7A and B](#f7-ott-11-5631){ref-type="fig"}).

Discussion
==========

ccRCC, which is characterized by its clear cell morphology phenotypic feature, has been related to lipid and glycogen accumulation.[@b27-ott-11-5631] Moreover, ccRCC is one of the most therapy-resistant cancers and responds very poorly or not at all to radiotherapy, chemotherapy and hormonal therapy.[@b28-ott-11-5631] Most ccRCC patients are diagnosed at a later stage, leading to ineffective treatments.[@b29-ott-11-5631] These facts emphasize the importance of developing novel prognostic biomarkers and therapeutic targets for ccRCC to improve the outcomes of patients.

Recent studies have shown that lncRNAs, defined as RNA transcripts over 200 nucleotides, are aberrantly expressed in ccRCC tissues and play pivotal roles in the regulation of ccRCC.[@b30-ott-11-5631],[@b31-ott-11-5631] They are associated with the pathogenesis, progression and metastasis of ccRCC. They are also involved in the tumorigenic process of ccRCC, including cell cycle control, cell proliferation, cell apoptosis, invasion and metastasis.[@b32-ott-11-5631]--[@b36-ott-11-5631] For example, MALAT1 was found to be upregulated in ccRCC tissues and to be associated with poor prognosis.[@b37-ott-11-5631] Conversely, lncRNA CADM1-AS1 functions as a tumor suppressor in ccRCC.[@b38-ott-11-5631] Many studies have demonstrated that abnormal expression levels of specific lncRNAs in ccRCC could serve as independent diagnostic and prognostic biomarkers.[@b39-ott-11-5631],[@b40-ott-11-5631] Recently, several studies have found that lncRNAs play a critical role in ccRCC tumorigenesis.[@b41-ott-11-5631]

The *DHRS4* gene cluster is localized on 14q11.2. The *DHRS4* gene codes for short-chain dehydrogenase/reductases that participate in retinoic acid and steroid pathways and are associated with cell proliferation, differentiation and tumorigenesis.[@b42-ott-11-5631] *DHRS4-AS1*, which is a head-to-head natural antisense transcript (NAT) of *DHRS4*, silences all three genes of the DHRS4 gene cluster (*DHRS4*, *DHRS4L2* and *DHRS4L1*) through the recruitment of epigenetic modifiers.[@b22-ott-11-5631],[@b23-ott-11-5631] Whether *DHRS4-AS1* affects tumor proliferation, differentiation, and cell cycle progression by manipulating the expression of DHRS4, thereby affecting the stability of retinoic acid, remains unknown. Little is known about the significance of *DHRS4-AS1* expression in carcinomas.

In the current study, we found that the expression of *DHRS4-AS1* was statistically lower in renal cancer cell lines and in ccRCC tissues than in the normal human proximal tubule epithelial cell line HK-2 and adjacent non-tumor tissues. Moreover, a lower *DHRS4-AS1* expression level is significantly associated with lymph node metastasis, a high TNM stage, advanced pathological grade and a poor overall survival. These data suggest that low *DHRS4-AS1* expression may serve as a novel indicator of poor prognosis in ccRCC and may be a potential therapeutic target for diagnosis and gene therapy. Then we tried to guess the reason which resulted in the downregulation of *DHRS4-AS1*, as methylation is the most common cause of gene silencing, so we browsed the UCSC data base and found there is methylation island in the promoter region of *DHRS4-AS1* ([Figure S1A](#SD1-ott-11-5631){ref-type="supplementary-material"}).[@b43-ott-11-5631],[@b44-ott-11-5631] Based on this prediction, we treated the cells with 5-azacytidine and DMSO as a control. After 72 h, the cells were harvested, then qRT-PCR was executed to estimate the expression of *DHRS4-AS1*, as shown in [Figure S1B](#SD1-ott-11-5631){ref-type="supplementary-material"} the expression of *DHRS4-AS1* was significantly downregulated in 5-azacytidine treatment group compare with the control group. These results suggest that the methylation of *DHRS4-AS1* promoter may be one of the reasons for its low expression in ccRCC.

One classic approach to exploring the putative functions of lncRNAs is through a "guilt-by-association" method.[@b45-ott-11-5631] This method associates lncRNAs with biological processes based on common expression patterns and identifies lncRNAs that are associated with specific cellular processes.[@b46-ott-11-5631],[@b47-ott-11-5631] To explore the function of *DHRS4-AS1* in ccRCC, our GSEA data indicated that *DHRS4-AS1* overexpression was negatively correlated with cell cycle genes and DNA replication genes ([Figure 3B and C](#f3-ott-11-5631){ref-type="fig"}). Cell cycle regulation is frequently abnormal in most common malignancies, resulting in aberrant cell proliferation.[@b48-ott-11-5631],[@b49-ott-11-5631] Here, *DHRS4-AS1* significantly promoted cell arrest in the G1 phase ([Figure 5A](#f5-ott-11-5631){ref-type="fig"}), suppressing the proliferation of ccRCC cells by inhibiting cell cycle progression. Meanwhile, *DHRS4-AS1* upregulation significantly suppressed the proliferation of ccRCC cells as shown by the CCK-8 assay. We then evaluated the effect of *DHRS4-AS1* on 786-O and 769-P cells relative to apoptosis. *DHRS4-AS1* upregulation increased the apoptosis of ccRCC cells, especially early apoptosis. Abundant evidence shows that retinoic acid inhibits cell cycle progression and induces the process of apoptosis in a variety of human cancer cells via various signaling pathways.[@b42-ott-11-5631] A potential explanation is that *DHRS4-AS1* can affect the stability of retinoic acid and subsequently play a role in inhibiting tumor growth and promoting apoptosis. The above data suggest that *DHRS4-AS1* may inhibit tumor growth by inhibiting the progression of the cell cycle, maintaining the tumor at a lower clinical grade and pathological stage ([Table 2](#t2-ott-11-5631){ref-type="table"}). In conclusion, *DHRS4-AS1* may be an important factor that affects tumor cell proliferation, suggesting that *DHRS4-AS1* is an important factor in ccRCC prognosis.

Invasion and metastasis are two of the most important hallmarks of malignant tumors and are directly correlated with mortality in human cancers.[@b50-ott-11-5631] In this study, low *DHRS4-AS1* expression was significantly correlated with lymph node metastasis in ccRCC ([Table 2](#t2-ott-11-5631){ref-type="table"}). To further explore the function of *DHRS4-AS1* in the ccRCC cell process, our in vitro experiments revealed that *DHRS4-AS1* overexpression significantly suppressed the invasion and migration capabilities of ccRCC cells by transwell assay. Therefore, our study suggests that *DHRS4-AS1* is an important regulator in controlling ccRCC cell metastasis. However, further studies are needed to identify the underlying molecular mechanisms of *DHRS4-AS1* in the metastasis of ccRCC.

Conclusion
==========

Collectively, we first identified the critical role of *DHRS4-AS1* in ccRCC. Our research found the following: 1) *DHRS4-AS1* was downregulated in ccRCC tissues and cell lines; 2) *DHRS4-AS1* expression was associated with lymph node metastasis, a high TNM stage and postoperative survival in renal cell cancer patients and 3) *DHRS4-AS1* upregulation significantly suppressed ccRCC cell proliferation, arrested the cell cycle, facilitated apoptosis and inhibited ccRCC cell migration. These data show that the lncRNA *DHRS4-AS1* exhibits antitumor activity and that *DHRS4-AS1* may be a novel target in ccRCC diagnostic and therapeutic strategies.

Supplementary materials
=======================

###### 

Promoter region methylation inhibits the expression of *DHRS4-AS1*.

**Notes:** (**A**) The UCSC data base and find there is methylation island in the promoter region of *DHRS4-AS1* (green represents CpG island). (**B**) 786-O and 769-P cells were treated with 4, 8 and 16 µM Aza and DMSO for 72 h, expression levels of *DHRS4-AS1* in 786-O and 769-P cells were examined by real-time PCR. ^\*^*P* \< 0.05; ^\*\*\*^*P* \< 0.001. The data are presented as the mean ± SD. Experiments were performed three times.

**Abbreviations:** UCSC, University of California Santa Cruz; *DHRS4-AS1*, DHRS4 antisense RNA 1; CpG, cytosine phosphate guanine; PCR, polymerase chain reaction; NS, no significance.

###### 

Associations of *DHRS4-AS1* expression with clinicopathological factors

  Characteristic          Number of patients, n (%)   *DHRS4-AS1*   *χ*^2^        *P*-value   
  ----------------------- --------------------------- ------------- ------------- ----------- ---------------------------------------------------
  Gender                  446 (100)                   223           223           0.039       0.844
   Male                   286 (64.13)                 144 (64.57)   142 (63.68)               
   Female                 160 (35.87)                 79 (35.43)    81 (36.32)                
  Age (years)                                                                     2.894       0.089
   ≤60                    218 (48.88)                 100 (44.84)   118 (52.91)               
   \>60                   228 (51.12)                 123 (55.16)   105 (47.09)               
  TNM stage                                                                       12.231      0.001[\*](#tfn7-ott-11-5631){ref-type="table-fn"}
   I--II                  275 (61.66)                 156 (69.96)   119 (53.36)               
   III--IV                171 (38.34)                 67 (30.04)    104 (46.6)                
  Lymph node metastasis                                                           0.153       0.696
   No                     218 (48.88)                 120 (93.75)   98 (92.45)                
   Yes                    16 (3.59)                   8 (6.25)      8 (7.55)                  
  Grade                                                                           6.023       0.014[\*](#tfn7-ott-11-5631){ref-type="table-fn"}
   G1--G2                 199 (44.62)                 113 (50.90)   86 (39.27)                
   G3--G4                 242 (54.26)                 109 (49.09)   133 (60.73)               

**Notes:**

*P* \< 0.05. -- indicates no data calculated.

**Abbreviations:** *DHRS4-AS1*, DHRS4 antisense RNA 1; TNM, tumour node metastasis.

###### 

Univariate and multivariate regression analyses of parameters associated with the prognosis of ccRCC patients

  Characteristics         Subset                    Univariate analysis    *P*-value                                             Multivariate analysis   *P*-value
  ----------------------- ------------------------- ---------------------- ----------------------------------------------------- ----------------------- -----------------------------------------------------
  Gender                  Male/female               0.985 (0.730--1.330)   0.922                                                 --                      --
  Age (years)             ≤60/\>60                  0.818 (0.633--1.059)   0.13                                                  --                      --
  Tumor stage             I+II/III+IV               3.628 (2.592--5.077)   \<0.001[\*](#tfn9-ott-11-5631){ref-type="table-fn"}   2.558 (1.589--4.120)    \<0.001[\*](#tfn9-ott-11-5631){ref-type="table-fn"}
  Tumor grade             Grade (1+2)/grade (3+4)   2.490 (1.700--3.648)   \<0.001[\*](#tfn9-ott-11-5631){ref-type="table-fn"}   2.052 (1.193--3.530)    0.009[\*](#tfn9-ott-11-5631){ref-type="table-fn"}
  Lymph node metastasis   Yes/no                    2.046 (1.021--4.100)   0.043[\*](#tfn9-ott-11-5631){ref-type="table-fn"}     --                      --
  *DHRS4-AS1*             High/low                  0.604 (0.433--0.843)   0.003[\*](#tfn9-ott-11-5631){ref-type="table-fn"}     --                      --

**Notes:**

*P* \< 0.05. -- indicates no data calculated.

**Abbreviations:** ccRCC, clear cell renal cell carcinoma; HR, hazard ratio; CI, confidence interval; *DHRS4-AS1*, DHRS4 antisense RNA 1.
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![*DHRS4-AS1* expression levels in renal cell lines and tissues.\
**Notes:** (**A**) *DHRS4-AS1* expression levels were examined by qRT-PCR and normalized to GAPDH expression in 52 paired ccRCC and adjacent normal tissue samples. (**B**) Relative expression of *DHRS4-AS1* between ccRCC (N = 446) and normal renal tissues (N = 67) from the TCGA database. (**C**) Relative expression of *DHRS4-AS1* between TNM Stages I+II (N = 39) and III+IV (N = 13) tissue samples. (**D**) Relative expression of *DHRS4-AS1* between TNM Stages I+II (N = 275) and III+IV (N = 171) tissue samples (TCGA). (**E**) Relative expression of *DHRS4-AS1* between Grades 1+2 (N = 37) and 3+4 (N = 15) tissue samples. (**F**) Relative expression of *DHRS4-AS1* between Grades 1+2 (N = 275) and 3+4 (N = 171) tissue samples. (**G**) Expression levels of *DHRS4-AS1* in the HK-2 cell line and two ccRCC cell lines were examined by real-time PCR. For all statistical analyses: ^\*^*P* \< 0.05; ^\*\*\*^*P* \< 0.001. The data are presented as the mean ± SD. Experiments were performed three times.\
**Abbreviations:** *DHRS4-AS1*, DHRS4 antisense RNA 1; qRT-PCR, quantitative real-time PCR; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; ccRCC, clear cell renal cell carcinoma; TCGA, The Cancer Genome Atlas; TNM, tumour node metastasis.](ott-11-5631Fig1){#f1-ott-11-5631}

![Association between *DHRS4-AS1* expression and clinicopathological characteristics and survival.\
**Notes:** (**A**) Kaplan--Meier survival curve based on high and low *DHRS4-AS1* expression in patients with ccRCC. "*DHRS4-AS1* low" (n = 26) represents the bottom of the cases, whereas "*DHRS4-AS1* high" (n = 26) is designated the top of the samples. (*P* = 0.0255). (**B**) Kaplan--Meier survival curve based on high and low *DHRS4-AS1* expression in patients with ccRCC (TCGA). "*DHRS4-AS1* low" (N = 223) represents the bottom of the cases, whereas "*DHRS4-AS1* high" (N = 223) is designated the top of the samples (*P* = 0.0027). (**C**) The ROC analysis revealed that a larger AUC for *DHRS4-AS1* in ccRCC indicates greater potential as a biomarker (AUC = 0.801).\
**Abbreviations:** *DHRS4-AS1*, DHRS4 antisense RNA 1; ccRCC, clear cell renal cell carcinoma; TCGA, The Cancer Genome Atlas; ROC, receiver operating characteristic; AUC, area under the curve.](ott-11-5631Fig2){#f2-ott-11-5631}

![The target gene enrichment of the KEGG pathways of the *DHRS4-AS1* signature.\
**Notes:** (**A**) The top 10 KEGG pathways with the highest normalized enrichment scores. GSEA plots presenting the inverse correlation between *DHRS4-AS1* expression and the negative regulation of cell cycle genes (**B**) and DNA replication genes in the TCGA KIRC data set (**C**).\
**Abbreviations:** *DHRS4-AS1*, DHRS4 antisense RNA 1; GSEA, Gene Set Enrichment Analysis; NES, normalized enrichment score; TCGA, The Cancer Genome Atlas.](ott-11-5631Fig3){#f3-ott-11-5631}

![Exogenetic *DHRS4-AS1* expression suppresses ccRCC cell proliferation and colony formation in vitro.\
**Notes:** (**A**) Real-time PCR analysis of *DHRS4-AS1* in 786-O and 769-P cells after exogenetic expression. (**B**) Ectopic *DHRS4-AS1* overexpression inhibits proliferation (**C**) and decreases colony formation in 786-O and 769-P cell lines. For all statistical analyses: ^\*^*P* \< 0.05; ^\*\*^*P* \< 0.01; ^\*\*\*^*P* \< 0.001. The data are presented as the mean ± SD. Experiments were performed three times.\
**Abbreviations:** *DHRS4-AS1*, DHRS4 antisense RNA 1; ccRCC, clear cell renal cell carcinoma; Lv, lentivirus.](ott-11-5631Fig4){#f4-ott-11-5631}

![Exogenetic *DHRS4-AS1* expression induced apoptosis and cell cycle arrest in ccRCC cells.\
**Notes:** (**A**) Flow cytometry was used to assess the cell cycle distribution of 786-O and 769-P cells transfected for 24 h and stained with PI. Representative and quantitative results are shown. (**B**) Flow cytometry was used to assess the percentage of apoptotic 786-O and 769-P cells after transfection for 48 h. Representative scatter plots and quantitative results are shown. n = 3; ^\*^*P* \< 0.05; ^\*\*^*P* \< 0.01.\
**Abbreviations:** *DHRS4-AS1*, DHRS4 antisense RNA 1; ccRCC, clear cell renal cell carcinoma; Lv, lentivirus; PI, propidium iodide; PE, phycoerythrin; Lin, linea.](ott-11-5631Fig5){#f5-ott-11-5631}

![Exogenetic *DHRS4-AS1* expression suppresses ccRCC cell migration.\
**Notes:** (**A** and **B**) In vitro wound-healing analysis in negative control, Flag or *DHRS4-AS1* cells. Representative photographs and quantitative results 24 h after generating the wound are presented. (**C** and **D**) The migration rate was also detected by transwell assay in negative control, Flag or *DHRS4-AS1* cells. Representative photographs and quantitative results are presented. For all statistical analyses: ^\*\*^*P* \< 0.01; ^\*\*\*^*P* \< 0.001. The data are presented as the mean ± SD. Experiments were performed three times.\
**Abbreviations:** *DHRS4-AS1*, DHRS4 antisense RNA 1; ccRCC, clear cell renal cell carcinoma; Lv, lentivirus.](ott-11-5631Fig6){#f6-ott-11-5631}

![*DHRS4-AS1* controls the expression of EMT-associated genes in ccRCC cells.\
**Notes:** (**A** and **B**) The expression levels of E-cadherin, N-cadherin and Vimentin in 786-O and 769-P cells were measured by using Western blot analysis. ^\*\*^*P* \< 0.01; ^\*\*\*^*P* \< 0.001. The data are presented as the mean ± SD. Experiments were performed three times.\
**Abbreviations:** *DHRS4-AS1*, DHRS4 antisense RNA 1; ccRCC, clear cell renal cell carcinoma; EMT, epithelial-mesenchymal transition; Lv, lentivirus.](ott-11-5631Fig7){#f7-ott-11-5631}

###### 

Seven lncRNAs significantly associated with overall survival

  Gene ID             Gene symbol       *P*-value                                              FDR        Coefficient
  ------------------- ----------------- ------------------------------------------------------ ---------- -------------
  ENSG00000215256.3   *DHRS4-AS1*       0.000336[\*](#tfn1-ott-11-5631){ref-type="table-fn"}   0.003595   −0.39807
  ENSG00000264885.1   *RP11-815I9.4*    0.003414[\*](#tfn1-ott-11-5631){ref-type="table-fn"}   0.018032   −0.41359
  ENSG00000236537.1   *RP11-732M18.3*   0.003303[\*](#tfn1-ott-11-5631){ref-type="table-fn"}   0.018032   −1.98674
  ENSG00000247556.2   *OIP5-AS1*        0.002565[\*](#tfn1-ott-11-5631){ref-type="table-fn"}   0.01716    −0.21251
  ENSG00000234912.5   *LINC00338*       0.005531[\*](#tfn1-ott-11-5631){ref-type="table-fn"}   0.024402   0.29512
  ENSG00000196696.8   *PDXDC2P*         0.004089[\*](#tfn1-ott-11-5631){ref-type="table-fn"}   0.019167   0.363749
  ENSG00000242125.2   *SNHG3*           0.000767[\*](#tfn1-ott-11-5631){ref-type="table-fn"}   0.007193   0.219547

**Note:**

*P* \< 0.05.

**Abbreviations:** lncRNAs, long noncoding RNAs; FDR, false discovery rate.

###### 

Associations of *DHRS4-AS1* expression with clinicopathological factors

  Characteristics         Number of patients   *DHRS4-AS1*   *χ*^2^       *P*-value   
  ----------------------- -------------------- ------------- ------------ ----------- ---------------------------------------------------
  Gender                                                                  0.08        0.777
   Male                   31                   15 (57.69)    16 (61.54)               
   Female                 21                   11 (42.31)    10 (38.46)               
  Age (years)                                                             0.391       0.532
   ≤65                    38                   20 (76.92)    18 (69.23)               
   \>65                   14                   6 (23.08)     8 (30.77)                
  TNM stage                                                               5.026       0.025[\*](#tfn3-ott-11-5631){ref-type="table-fn"}
   I+II                   39                   23 (88.46)    16 (61.54)               
   III+IV                 13                   3 (11.54)     10 (38.46)               
  Grade                                                                   4.591       0.032[\*](#tfn3-ott-11-5631){ref-type="table-fn"}
   Grade 1+2              37                   22 (84.62)    15 (57.69)               
   Grade 3+4              15                   4 (15.38)     11 (42.31)               
  Lymph node metastasis                                                   3.9         0.048[\*](#tfn3-ott-11-5631){ref-type="table-fn"}
   No                     40                   23 (88.46)    17 (65.38)               
   Yes                    12                   3 (11.54)     9 (34.62)                
  Distant metastasis                                                      0           1
   M0                     48                   24 (92.31)    24 (92.31)               
   M1                     4                    2 (7.69)      2 (7.69)                 

**Note:**

*P* \< 0.05.

**Abbreviations:** *DHRS4-AS1*, DHRS4 antisense RNA 1; TNM, tumour node metastasis.

###### 

Univariate and multivariate regression analyses of parameters associated with the prognosis of ccRCC patients

  Characteristic          Subset                    Univariate analysis     Multivariate analysis                                                        
  ----------------------- ------------------------- ----------------------- ----------------------------------------------------- ---------------------- -----------------------------------------------------
  Gender                  Male/female               0.956 (0.409--2.237)    0.918                                                 --                     --
  Age (years)             ≤60/\>60                  0.443 (0.174--1.126)    0.443                                                 --                     --
  Tumor stage             I+II/III+IV               7.381 (2.941--18.525)   \<0.001[\*](#tfn5-ott-11-5631){ref-type="table-fn"}   2.558 (1.589--4.120)   \<0.001[\*](#tfn5-ott-11-5631){ref-type="table-fn"}
  Tumor grade             Grade (1+2)/grade (3+4)   2.373 (1.014--5.556)    0.046[\*](#tfn5-ott-11-5631){ref-type="table-fn"}     --                     --
  Lymph node metastasis   Yes/no                    6.034 (2.503--14.543)   \<0.001[\*](#tfn5-ott-11-5631){ref-type="table-fn"}   --                     --
  Distant metastasis      Yes/no                    5.444 (1.966--15.075)   0.001[\*](#tfn5-ott-11-5631){ref-type="table-fn"}     --                     --
  *DHRS4-AS1*             High/low                  0.407 (0.173--0.960)    0.04[\*](#tfn5-ott-11-5631){ref-type="table-fn"}      --                     --

**Notes:**

*P* \< 0.05. -- indicates no data calculated.

**Abbreviations:** ccRCC, clear cell renal cell carcinoma; HR, hazard ratio; CI, confidence interval; *DHRS4-AS1*, DHRS4 antisense RNA 1.
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